Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
2019 · Annals of Oncology · 161 citations
https://doi.org/10.1093/annonc/mdz278
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
19
Papers
577
Citations
6
h-index
3
i10-index
Robert J. Hoyer is an academic researcher from University of Colorado Health. The author has contributed to research in topics: Lung Cancer Research Studies & Cancer Immunotherapy and Biomarkers & Neuroendocrine Tumor Research Advances. The author has an h-index of 6, co-authored 17 publications.
https://doi.org/10.1093/annonc/mdz278
https://doi.org/10.1038/s41416-025-02990-x
Click to start Chat